Originally founded in 1985 as Ethical Holdings (a pure play drug delivery company), the company changed its name to Amarin in December 1999 to reflect the change in strategy to specialty pharmaceuticals. Amarin is listed on the Nasdaq small cap market (ticker: AMRN), has headquarters in London and a research and development facility in Stirling, Scotland. In October 2004, Amarin has successfully closed the acquisition of Laxdale, a private neuroscience development company based in Stirling, Scotland. The transaction provides Amarin with a significant neuroscience pipeline in clinical development for central nervous system disorders, including Miraxion(TM), which is in phase III development for Huntington's disease. Also in October 2004 , Amarin completed a private placement of 13,448,546 ordinary shares to a group of new and existing accredited investors and management, raising gross proceeds to the company of $12.75 million. The purchase price of $0.947 per share was based on the average closing price of Amarin's American Depositary Shares on Nasdaq for the ten trading days ending 6th October 2004. Amarin is committed to improving the lives of patients suffering from diseases of the central nervous system. The company's goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs.